China Medical Technologies was granted approval by the SFDA for its real-time PCR-based Epidermal Growth Factor Receptor Assay. The EGFR PCR Assay is used to detect the 28 most common mutations in the EGFR gene in patients with non-small cell lung cancer, predicting the efficacy of targeted cancer drugs. EGFR abnormalities have been found in approximately 85% of NSCLC patients who responded to Iressa or Tarceva. More details....

Stock Symbol: (NSDQ: CMED)